ELV:NYE- (USD)

COMMON STOCK | Healthcare Plans |

Last Closing

USD 377.95

Change

+1.97 (+0.52)%

Market Cap

USD 84.11B

Volume

2.16M
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-28 )

Largest Industry Peers for Healthcare Plans

Symbol Name Price(Change) Market Cap
UNH UnitedHealth Group Incorporate..

+3.74 (+1.25%)

USD 268.12B
CNC Centene Corp

-0.08 (-0.14%)

USD 28.07B
MOH Molina Healthcare Inc

+1.17 (+0.39%)

USD 16.54B
OSCR Oscar Health Inc

N/A

USD 4.46B
NEUE NeueHealth Inc

+0.02 (+0.29%)

USD 0.06B
CI Cigna Corp

+4.59 (+1.47%)

N/A
CVS CVS Health Corp

+1.26 (+2.01%)

N/A
HUM Humana Inc

+3.05 (+1.33%)

N/A

ETFs Containing ELV

CAMX Cambiar Aggressive Value .. 5.69 % 0.00 %

-0.01 (-0.30%)

USD 0.06B
ZWHC:CA BMO Covered Call Health C.. 4.88 % 0.00 %

-0.15 (-0.30%)

N/A
WHCS:SW iShares MSCI World Health.. 3.67 % 0.00 %

N/A

N/A
CBUF:F iShares V Public Limited .. 3.37 % 0.00 %

+0.04 (+-0.30%)

N/A
AILV 3.21 % 0.00 %

N/A

N/A
WELG:XETRA Amundi S&P Global Health .. 2.53 % 0.00 %

+0.06 (+-0.30%)

N/A
WELS:XETRA Amundi S&P Global Health .. 2.53 % 0.00 %

+0.07 (+-0.30%)

N/A
FEGE The RBB Fund Trust 2.35 % 0.00 %

-0.12 (-0.30%)

N/A
H41D:XETRA HSBC MSCI World Value ESG.. 2.16 % 0.00 %

-0.04 (-0.30%)

N/A
ESGI:AU VanEck MSCI International.. 1.96 % 0.00 %

-0.09 (-0.30%)

USD 0.19B
VMAX REX VolMAXX Long VIX Futu.. 1.80 % 0.00 %

+1.23 (+-0.30%)

USD 0.05B
PAPI Morgan Stanley ETF Trust 0.70 % 0.00 %

-0.28 (-0.30%)

USD 0.19B
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

+0.40 (+-0.30%)

N/A
FHI:CA CI Health Care Giants Cov.. 0.00 % 0.75 %

+0.13 (+-0.30%)

CAD 0.10B
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.00 %

N/A

CAD 0.05B
RYH 0.00 % 0.40 %

N/A

N/A
UBUS:F UBS (Irl) ETF Public Limi.. 0.00 % 0.00 %

+0.02 (+-0.30%)

USD 0.15B
UBUW:F UBS (Irl) ETF Public Limi.. 0.00 % 0.00 %

N/A

USD 0.01B
PBI-B:CA Purpose Fund Corp. - Purp.. 0.00 % 0.00 %

-0.82 (-0.30%)

N/A
TEQI T. Rowe Price Equity Inco.. 0.00 % 0.00 %

+0.08 (+-0.30%)

USD 0.30B
CBUF:XETRA iShares MSCI World Health.. 0.00 % 0.00 %

+0.05 (+-0.30%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Healthcare Plans) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.45% 56% F 69% C-
Dividend Return 0.46% 60% D- 18% F
Total Return 2.92% 56% F 68% D+
Trailing 12 Months  
Capital Gain -25.24% 44% F 12% F
Dividend Return 1.31% 40% F 27% F
Total Return -23.93% 44% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.61% 33% F 28% F
Dividend Return -0.92% 22% F 20% F
Total Return 0.69% 20% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 11.85% 89% A- 73% C
Risk Adjusted Return -7.78% 22% F 19% F
Market Capitalization 84.11B 83% B 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector